Evidence map›Paper›PMID 25811463›Full record

ArticlePLoS genetics2015

NLRC5 exclusively transactivates MHC class I and related genes through a distinctive SXY module.

Kristina Ludigs, Queralt Seguín-Estévez, Sylvain Lemeille, Isabel Ferrero, Giorgia Rota, Sonia Chelbi, Chantal Mattmann, H Robson MacDonald, Walter Reith, Greta Guarda

Open access · goldAbstract read
In one paragraph

Article in PLoS genetics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed, 1 pooled it
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

59 citing papers in PubMed, 1 synthesis or guideline pooled it, 102 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Adaptation of the Tumor Antigen Presentation Machinery to Ionizing Radiation.Journal of immunology (Baltimore, Md. : 1950) · 2023
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Kristina LudigsDepartment of Biochemistry, University of Lausanne, Epalinges, Switzerland.
Queralt Seguín-EstévezDepartment of Pathology and Immunology, University of Geneva Medical School, Geneva, Switzerland.
Sylvain LemeilleDepartment of Pathology and Immunology, University of Geneva Medical School, Geneva, Switzerland.
Isabel FerreroLudwig Center for Cancer Research of the University of Lausanne, Epalinges, Switzerland.
Giorgia RotaDepartment of Biochemistry, University of Lausanne, Epalinges, Switzerland.
Sonia ChelbiDepartment of Biochemistry, University of Lausanne, Epalinges, Switzerland.
Chantal MattmannDepartment of Biochemistry, University of Lausanne, Epalinges, Switzerland.
H Robson MacDonaldLudwig Center for Cancer Research of the University of Lausanne, Epalinges, Switzerland.
Walter ReithDepartment of Pathology and Immunology, University of Geneva Medical School, Geneva, Switzerland.
Greta GuardaDepartment of Biochemistry, University of Lausanne, Epalinges, Switzerland.
University of Lausanne · CHUniversity of Geneva · CHLudwig Cancer Research · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MHC class II (MHCII) genes are transactivated by the NOD-like receptor (NLR) family member CIITA, which is recruited to SXY enhancers of MHCII promoters via a DNA-binding "enhanceosome" complex. NLRC5, another NLR protein, was recently found to control transcription of MHC class I (MHCI) genes. However, detailed understanding of NLRC5's target gene specificity and mechanism of action remained lacking. We performed ChIP-sequencing experiments to gain comprehensive information on NLRC5-regulated genes. In addition to classical MHCI genes, we exclusively identified novel targets encoding non-classical MHCI molecules having important functions in immunity and tolerance. ChIP-sequencing performed with Rfx5(-/-) cells, which lack the pivotal enhanceosome factor RFX5, demonstrated its strict requirement for NLRC5 recruitment. Accordingly, Rfx5-knockout mice phenocopy Nlrc5 deficiency with respect to defective MHCI expression. Analysis of B cell lines lacking RFX5, RFXAP, or RFXANK further corroborated the importance of the enhanceosome for MHCI expression. Although recruited by common DNA-binding factors, CIITA and NLRC5 exhibit non-redundant functions, shown here using double-deficient Nlrc5(-/-)CIIta(-/-) mice. These paradoxical findings were resolved by using a "de novo" motif-discovery approach showing that the SXY consensus sequence occupied by NLRC5 in vivo diverges significantly from that occupied by CIITA. These sequence differences were sufficient to determine preferential occupation and transactivation by NLRC5 or CIITA, respectively, and the S box was found to be the essential feature conferring NLRC5 specificity. These results broaden our knowledge on the transcriptional activities of NLRC5 and CIITA, revealing their dependence on shared enhanceosome factors but their recruitment to distinct enhancer motifs in vivo. Furthermore, we demonstrated selectivity of NLRC5 for genes encoding MHCI or related proteins, rendering it an attractive target for therapeutic intervention. NLRC5 and CIITA thus emerge as paradigms for a novel class of transcriptional regulators dedicated for transactivating extremely few, phylogenetically related genes.

Indexed as

Genes, MHC Class IGenes, MHC Class IIAnimalsB-LymphocytesDNA-Binding ProteinsEnhancer Elements, GeneticGene Expression RegulationGenomeIntracellular Signaling Peptides and ProteinsMiceNuclear ProteinsPromoter Regions, GeneticT-LymphocytesTrans-ActivatorsTranscriptional ActivationDNA-Binding ProteinsIntracellular Signaling Peptides and ProteinsMHC class II transactivator proteinNLRC5 protein, mouseNuclear ProteinsTrans-Activators

Identifiers

PMID25811463
PMCPMC4374748
OpenAlexW2017075227

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.